IRIS UniCatt

Coratti, Giorgia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.021
EU - Europa 5.794
AS - Asia 5.359
SA - Sud America 1.043
Continente sconosciuto - Info sul continente non disponibili 251
AF - Africa 148
OC - Oceania 11
Totale 20.627
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.665
SG - Singapore 2.536
IT - Italia 1.463
DE - Germania 1.262
CN - Cina 1.038
BR - Brasile 800
NL - Olanda 787
SE - Svezia 610
VN - Vietnam 552
FR - Francia 459
IE - Irlanda 258
GB - Regno Unito 226
JP - Giappone 184
CA - Canada 181
IN - India 177
HK - Hong Kong 148
BD - Bangladesh 141
FI - Finlandia 136
ID - Indonesia 135
RU - Federazione Russa 105
PL - Polonia 101
AR - Argentina 87
MX - Messico 83
TR - Turchia 76
ES - Italia 73
KR - Corea 69
IQ - Iraq 52
AT - Austria 48
ZA - Sudafrica 44
UA - Ucraina 40
EC - Ecuador 39
CO - Colombia 38
PK - Pakistan 32
CZ - Repubblica Ceca 31
BE - Belgio 28
CH - Svizzera 27
VE - Venezuela 27
PH - Filippine 25
IR - Iran 24
LT - Lituania 24
SA - Arabia Saudita 20
IL - Israele 18
PA - Panama 18
PY - Paraguay 18
RO - Romania 18
AE - Emirati Arabi Uniti 17
MA - Marocco 17
EG - Egitto 16
JM - Giamaica 16
CR - Costa Rica 15
RS - Serbia 15
UZ - Uzbekistan 15
CI - Costa d'Avorio 14
TN - Tunisia 14
JO - Giordania 13
MK - Macedonia 13
PE - Perù 13
KE - Kenya 11
PT - Portogallo 11
TH - Thailandia 11
CL - Cile 10
NP - Nepal 10
MY - Malesia 9
DO - Repubblica Dominicana 8
AL - Albania 7
BG - Bulgaria 7
DK - Danimarca 7
HN - Honduras 7
KZ - Kazakistan 7
OM - Oman 7
NZ - Nuova Zelanda 6
TT - Trinidad e Tobago 6
UY - Uruguay 6
LB - Libano 5
LK - Sri Lanka 5
NG - Nigeria 5
SK - Slovacchia (Repubblica Slovacca) 5
SV - El Salvador 5
AU - Australia 4
BY - Bielorussia 4
DZ - Algeria 4
ET - Etiopia 4
GR - Grecia 4
GT - Guatemala 4
HU - Ungheria 4
KG - Kirghizistan 4
LV - Lettonia 4
QA - Qatar 4
SN - Senegal 4
TW - Taiwan 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AZ - Azerbaigian 3
BH - Bahrain 3
BO - Bolivia 3
GE - Georgia 3
LA - Repubblica Popolare Democratica del Laos 3
LU - Lussemburgo 3
ME - Montenegro 3
NI - Nicaragua 3
XK - ???statistics.table.value.countryCode.XK??? 3
Totale 20.334
Salva come PNG Salva come JPEG
Città #
Singapore 1.553
Ashburn 935
San Jose 784
Amsterdam 707
Chandler 597
Los Angeles 373
Rome 337
New York 335
Frankfurt am Main 310
Dublin 229
Beijing 201
Milan 197
Hefei 181
Ho Chi Minh City 181
Tokyo 177
Hong Kong 134
Hanoi 129
Lauterbourg 127
Tukwila 120
Jakarta 117
Dallas 108
Munich 91
São Paulo 88
Boston 87
Atlanta 77
Chicago 77
Santa Clara 77
Buffalo 76
Helsinki 74
Warsaw 70
Marseille 68
Orem 67
Seoul 66
The Dalles 62
Montreal 61
Council Bluffs 59
Princeton 58
San Mateo 56
Houston 52
Boardman 48
Denver 48
Kent 48
Moscow 48
Brooklyn 47
London 46
Phoenix 45
Nuremberg 42
Poplar 41
Stockholm 41
Toronto 39
Wilmington 39
Paris 38
Chennai 35
Düsseldorf 35
Palermo 35
Da Nang 33
Johannesburg 30
Mexico City 30
Bremen 28
Haiphong 28
Lappeenranta 26
Nanjing 26
San Francisco 26
Turku 25
Pune 24
Turin 24
Shanghai 23
Ann Arbor 22
Dearborn 22
Ankara 21
Brussels 21
Columbus 21
Baghdad 20
Belo Horizonte 20
Brno 20
Memphis 20
Vienna 20
Bologna 19
Brasília 19
Fairfield 19
Rio de Janeiro 19
Seattle 19
Charlotte 18
Biên Hòa 17
Dhaka 17
Falkenstein 17
Florence 17
Guangzhou 17
Naples 17
Washington 16
Istanbul 15
Kish 15
Las Vegas 15
New Delhi 15
Quito 15
Abidjan 14
Bexley 14
Hyderabad 14
Manchester 14
Querétaro 14
Totale 10.679
Salva come PNG Salva come JPEG
Nome #
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 1.047
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial 737
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 507
Predictive models in SMA II natural history trajectories using machine learning: A proof of concept study 362
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module 342
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 317
Myostatin Levels in SMA Following Disease-Modifying Treatments: A Multi-Center Study 310
Language Development in Preschool Duchenne Muscular Dystrophy Boys 306
Longitudinal natural history of type I spinal muscular atrophy: A critical review 269
Performance of Upper Limb module for Duchenne muscular dystrophy 259
Assessing floppy infants: a new module 221
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 207
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 199
Developmental milestones in type I spinal muscular atrophy 193
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 190
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 182
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 178
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 178
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 173
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 173
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 172
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 169
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 167
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 166
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 164
Hammersmith Infant Neurological Examination in low-risk infants born very preterm: a longitudinal prospective study 162
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study 161
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 159
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 159
Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World Data 158
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 158
Respiratory function and therapeutic expectations in DMD: Families experience and perspective 153
The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy 152
Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. 151
Bulbar function in spinal muscular atrophy (SMA): State of art and new challenges. 21st July 2023, Rome, Italy 150
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 149
A Longitudinal Follow-Up Study of Intellectual Function in Duchenne Muscular Dystrophy over Age: Is It Really Stable? 149
Revised upper limb module for spinal muscular atrophy: Development of a new module 148
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 148
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 148
Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3 147
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 147
2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants 146
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 146
Early Gross Motor Milestones in Duchenne Muscular Dystrophy 146
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016 146
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 145
Early treatment of type II SMA slows rate of progression of scoliosis 144
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 144
Early Childhood Attention Battery: Italian adaptation and new expanded normative data. 144
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. 143
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 142
Longitudinal motor functional outcomes and magnetic resonance imaging patterns of muscle involvement in upper limbs in duchenne muscular dystrophy 141
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 139
High Expression of SMN circ4-2b-3 in SMA I Children Treated with Nusinersen is Associated with Improved Motor Outcomes 137
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 137
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 137
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 137
Functional levels and MRI patterns of muscle involvement in upper limbs in Duchenne muscular dystrophy. 136
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 135
Early Childhood Attention Battery: Italian adaptation and new expanded normative data. 135
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 135
Prevalence of Duchenne muscular dystrophy in Italy: a nationwide survey 134
Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study 134
Assessment of early attention in an Italian cohort of preschooler preterm children using the Early Childhood Attention Battery 133
An observational study of functional abilities in infants, children, and adults with type 1 SMA. 133
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 133
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 132
Communicative development inventory in type 1 and presymptomatic infants with spinal muscular atrophy: a cohort study 131
Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53 131
Italian survey on evolving SMA care with disease-modifying therapies: a consensus workshop on nutrition, swallowing, respiratory and rehabilitation care 131
A Longitudinal Follow-Up Study of Intellectual Function in Duchenne Muscular Dystrophy over Age: Is It Really Stable? 130
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 130
Language Development in Preschool Duchenne Muscular Dystrophy Boys 128
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial 128
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 128
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 127
Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study 125
Long‐term natural history in type II and III spinal muscular atrophy: a 4‐year international study on the Hammersmith Functional Motor Scale Expanded 125
Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy? 124
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 122
Developmental milestones in type I spinal muscular atrophy 121
Longitudinal natural history in young boys with Duchenne muscular dystrophy 121
Sleep disorders in spinal muscular atrophy 119
Development of an International SMA Bulbar Assessment for Inter-professional Administration 119
Revised upper limb module for spinal muscular atrophy: Development of a new module 119
Longitudinal Motor Functional Outcomes and Magnetic Resonance Imaging Patterns of Muscle Involvement in Upper Limbs in Duchenne Muscular Dystrophy. 119
Clinical Variability in Spinal Muscular Atrophy Type III. 118
Development of an academic disease registry for spinal muscular atrophy 117
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 117
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 117
An observational study of functional abilities in infants, children, and adults with type 1 SMA 116
Development of the SMA EFFORT: A new approach to characterize perceived physical fatigability in spinal muscular atrophy 114
Patient reported outcome measure for upper limb in Duchenne muscular dystrophy: correlation with PUL2.0 111
Clinical Phenotype of Pediatric and Adult Patients With Spinal Muscular Atrophy With Four SMN2 Copies: Are They Really All Stable? 111
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 111
Risdiplam in Type 1 Spinal Muscular Atrophy 109
P.222Long term progression in type II spinal muscular atrophy: a retrospective observational study 108
Upper Limb Changes in DMD Patients Amenable to Skipping Exons 44, 45, 51 and 53: A 24-Month Study 108
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 107
Totale 17.243
Salva come PNG Salva come JPEG
Categoria #
all - tutte 82.002
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 82.002
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022641 0 0 15 92 52 27 17 95 50 41 122 130
2022/20232.030 179 245 123 273 135 262 143 182 277 37 102 72
2023/20241.666 60 299 70 140 76 297 196 83 42 86 130 187
2024/20253.182 64 53 217 197 247 170 166 135 425 251 668 589
2025/202610.634 954 294 588 1.277 1.793 1.997 1.453 427 468 508 506 369
2026/20272.084 447 1.337 300 0 0 0 0 0 0 0 0 0
Totale 20.627